Jacques Fellay

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil

94 publications

In press | 2019 | 2018 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate.
Dietrich L.G., Barceló C., Thorball C.W., Ryom L., Burkhalter F., Hasse B., Furrer H., Weisser M., Steffen A., Bernasconi E. et al. Clinical infectious diseases. Peer-reviewed.
HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected.
Nguyen H., Thorball C.W., Fellay J., Böni J., Yerly S., Perreau M., Klimkait T., Kusejko K., Bachmann N., Chaudron S.E. et al., 2019/08/15. Journal of acquired immune deficiency syndromes, 81 (5) pp. 508-515. Peer-reviewed.
Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.
Bachmann N., von Siebenthal C., Vongrad V., Turk T., Neumann K., Beerenwinkel N., Bogojeska J., Fellay J., Roth V., Kok Y.L. et al., 2019/07/19. Nature communications, 10 (1) p. 3193. Peer-reviewed.
Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients.
Asgari S., Chaturvedi N., Scepanovic P., Hammer C., Semmo N., Giostra E., Müllhaupt B., Angus P., Thompson A.J., Moradpour D. et al., 2019/02. Journal of viral hepatitis, 26 (2) pp. 271-277. Peer-reviewed.
Effect of Fc Receptor Genetic Diversity on HIV-1 Disease Pathogenesis.
Geraghty D.E., Thorball C.W., Fellay J., Thomas R., 2019. Frontiers in immunology, 10 p. 970. Peer-reviewed.
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines.
Scepanovic P., Alanio C., Hammer C., Hodel F., Bergstedt J., Patin E., Thorball C.W., Chaturvedi N., Charbit B., Abel L. et al., 2018/07/27. Genome medicine, 10 (1) p. 59. Peer-reviewed.
Detection of novel astroviruses MLB1 and MLB2 in the sera of febrile Tanzanian children.
Cordey S., Hartley M.A., Keitel K., Laubscher F., Brito F., Junier T., Kagoro F., Samaka J., Masimba J., Said Z. et al., 2018/03/14. Emerging microbes & infections, 7 (1) p. 27. Peer-reviewed.
Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord, 2018/02/01. Clinical infectious diseases, 66 (4) pp. 594-603. Peer-reviewed.
Médecine génomique : les enjeux de l’information en pratique clinique [Genomic medicine : the challenges of information in clinical practice]
Guessous I., Mooser V., Fellay J., Bochud M., Simeoni U., Unger S., Waeber G., Cornuz J., 2016/11/02. Revue medicale suisse, 12 (537) pp. 1838-1844. Peer-reviewed.
Determinants of HIV-1 broadly neutralizing antibody induction.
Rusert P., Kouyos R.D., Kadelka C., Ebner H., Schanz M., Huber M., Braun D.L., Hozé N., Scherrer A., Magnus C. et al., 2016/11. Nature medicine, 22 (11) pp. 1260-1267. Peer-reviewed.
Médecine génomique : les enjeux de l’information en pratique clinique
Guessous I., Mooser V., Fellay J., Bochud M., Simeoni U., Unger S., Waeber G., Cornuz J., 2016/11. Revue médicale suisse, 12 (537) pp. 1838-1844.
Identification of Siglec-1 null individuals infected with HIV-1
Martinez-Picado Javier, McLaren Paul J., Erkizia Itziar, Martin Maureen P., Benet Susana, Rotger Margalida, Dalmau Judith, Ouchi Dan, Wolinsky Steven M., Penugonda Sudhir et al., 2016/08/11. Nature Communications, 7 p. 12412.
Privacy-preserving genomic testing in the clinic: a model using HIV treatment.
McLaren P.J., Raisaro J.L., Aouri M., Rotger M., Ayday E., Bartha I., Delgado M.B., Vallet Y., Günthard H.F., Cavassini M. et al., 2016/08. Genetics in medicine, 18 (8) pp. 814-822. Peer-reviewed.
Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study.
Junier T., Rotger M., Biver E., Ledergerber B., Barceló C., Bartha I., Kovari H., Schmid P., Fux C., Bernasconi E. et al., 2016. Open Forum Infectious Diseases, 3 (2) pp. ofw101. Peer-reviewed.
Opportunistic testing for urogenital infection with Chlamydia trachomatis in south-western Switzerland, 2012 : a feasibility study
Bally F., Quach A., Greub G., Jaton K., Petignat C., Ambord C., Fellay J., Masserey E., Spencer B., 2015. Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 20 (9) pp. pii21051. Peer-reviewed.
The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals.
Perkins M.R., Bartha I., Timmer J.K., Liebner J.C., Wollinsky D., Günthard H.F., Hauser C., Bernasconi E., Hoffmann M., Calmy A. et al., 2015. Journal of Infectious Diseases, 212 (4) pp. 578-584. Peer-reviewed.
A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression.
Braun D.L., Kouyos R., Oberle C., Grube C., Joos B., Fellay J., McLaren P.J., Kuster H., Günthard H.F., 2014. PLoS One, 9 (12) pp. e114111.
Analysis of stop-gain and frameshift variants in human innate immunity genes.
Rausell A., Mohammadi P., McLaren P.J., Bartha I., Xenarios I., Fellay J., Telenti A., 2014. Plos Computational Biology, 10 (7) pp. e1003757. Peer-reviewed.
Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.
Hasse B., Walker A.S., Fehr J., Furrer H., Hoffmann M., Battegay M., Calmy A., Fellay J., Di Benedetto C., Weber R. et al., 2014. Antimicrobial Agents and Chemotherapy, 58 (4) pp. 2363-2368. Peer-reviewed.
Disentangling human tolerance and resistance against HIV.
Regoes R.R., McLaren P.J., Battegay M., Bernasconi E., Calmy A., Günthard H.F., Hoffmann M., Rauch A., Telenti A., Fellay J. et al., 2014. Plos Biology, 12 (9) pp. e1001951. Peer-reviewed.
Dynamics of HIV latency and reactivation in a primary CD4+ T cell model.
Mohammadi P., di Iulio J., Muñoz M., Martinez R., Bartha I., Cavassini M., Thorball C., Fellay J., Beerenwinkel N., Ciuffi A. et al., 2014. Plos Pathogens, 10 (5) pp. e1004156.
GuavaH: a compendium of host genomic data in HIV biology and disease.
Bartha I., McLaren P.J., Ciuffi A., Fellay J., Telenti A., 2014. Retrovirology, 11 p. 6. Peer-reviewed.
HLA class I and KIR genes do not protect against HIV type 1 infection in highly exposed uninfected individuals with hemophilia A.
Vince N., Bashirova A.A., Lied A., Gao X., Dorrell L., McLaren P.J., Fellay J., Carrington M., 2014. Journal of Infectious Diseases, 210 (7) pp. 1047-1051. Peer-reviewed.
LILRB2 interaction with HLA class I correlates with control of HIV-1 infection.
Bashirova A.A., Martin-Gayo E., Jones D.C., Qi Y., Apps R., Gao X., Burke P.S., Taylor C.J., Rogich J., Wolinsky S. et al., 2014. Plos Genetics, 10 (3) pp. e1004196. Peer-reviewed.
Médecine génomique et Maladies infectieuses [Genomic medicine and infectious diseases].
Fellay J., 2014. Praxis, 103 (10) pp. 587-590. Peer-reviewed.
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control.
Bartha I., Carlson J.M., Brumme C.J., McLaren P.J., Brumme Z.L., John M., Haas D.W., Martinez-Picado J., Dalmau J., López-Galíndez C. et al., 2013. eLIFE, 2 pp. e01123. Peer-reviewed.
A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.
Lane J., McLaren P.J., Dorrell L., Shianna K.V., Stemke A., Pelak K., Moore S., Oldenburg J., Alvarez-Roman M.T., Angelillo-Scherrer A. et al., 2013. Human Molecular Genetics, 22 (9) pp. 1903-1910.
Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls.
McLaren P.J., Coulonges C., Ripke S., van den Berg L., Buchbinder S., Carrington M., Cossarizza A., Dalmau J., Deeks S.G., Delaneau O. et al., 2013. Plos Pathogens, 9 (7) pp. e1003515.
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
Rotger M., Glass T.R., Junier T., Lundgren J., Neaton J.D., Poloni E.S., van 't Wout A.B., Lubomirov R., Colombo S., Martinez R. et al., 2013. Clinical Infectious Diseases, 57 (1) pp. 112-121. Peer-reviewed.
European genetic diversity and susceptibility to pathogens.
McLaren P.J., Fellay J., Telenti A., 2013. Human Heredity, 76 (3-4) pp. 187-193.
Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease.
Kulkarni S., Qi Y., O'huigin C., Pereyra F., Ramsuran V., McLaren P., Fellay J., Nelson G., Chen H., Liao W. et al., 2013. Proceedings of the National Academy of Sciences of the United States of America, 110 (51) pp. 20705-20710. Peer-reviewed.
Influence of HLA-C expression level on HIV control.
Apps R., Qi Y., Carlson J.M., Chen H., Gao X., Thomas R., Yuki Y., Del Prete G.Q., Goulder P., Brumme Z.L. et al., 2013. Science, 340 (6128) pp. 87-91. Peer-reviewed.
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
Thompson A.J., Clark P.J., Singh A., Ge D., Fellay J., Zhu M., Zhu Q., Urban T.J., Patel K., Tillmann H.L. et al., 2012. Journal of Hepatology, 56 (2) pp. 313-319.
HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption.
Stern M., Czaja K., Rauch A., Rickenbach M., Günthard H.F., Battegay M., Fellay J., Hirschel B., Hess C., the Swiss HIV Cohort Study Group, 2012. HIV Medicine, 13 (10) pp. 589-595.
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
Clark P.J., Thompson A.J., Zhu M., Vock D.M., Zhu Q., Ge D., Patel K., Harrison S.A., Urban T.J., Naggie S. et al., 2012. Journal of Viral Hepatitis, 19 (5) pp. 332-340.
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.
Pillai S.K., Abdel-Mohsen M., Guatelli J., Skasko M., Monto A., Fujimoto K., Yukl S., Greene W.C., Kovari H., Rauch A. et al., 2012. Proceedings of the National Academy of Sciences of the United States of America, 109 (8) pp. 3035-3040.
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.
Clark P.J., Thompson A.J., Zhu Q., Vock D.M., Zhu M., Patel K., Harrison S.A., Naggie S., Ge D., Tillmann H.L. et al., 2012. Digestive Diseases and Sciences, 57 (8) pp. 2213-2221.
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.
di Iulio J., Ciuffi A., Fitzmaurice K., Kelleher D., Rotger M., Fellay J., Martinez R., Pulit S., Furrer H., Günthard H.F. et al., 2011/05. Hepatology, 53 (5) pp. 1446-1454. Peer-reviewed.
A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease.
Vanasse G.J., Jeong J.Y., Tate J., Bathulapalli H., Anderson D., Steen H., Fleming M., Mattocks K., Telenti A., Fellay J. et al., 2011. Blood, 118 (20) pp. 5401-5408.
Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population.
Petrovski S., Fellay J., Shianna K.V., Carpenetti N., Kumwenda J., Kamanga G., Kamwendo D.D., Letvin N.L., McMichael A.J., Haynes B.F. et al., 2011. Aids, 25 (4) pp. 513-518.
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque.
Rotger M., Dalmau J., Rauch A., McLaren P., Bosinger S.E., Martinez R., Sandler N.G., Roque A., Liebner J., Battegay M. et al., 2011. Journal of Clinical Investigation, 121 (6) pp. 2391-2400.
Copy number variation of KIR genes influences HIV-1 control.
Pelak K., Need A.C., Fellay J., Shianna K.V., Feng S., Urban T.J., Ge D., De Luca A., Martinez-Picado J., Wolinsky S.M. et al., 2011. Plos Biology, 9 (11) pp. e1001208.
Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages.
Bol S.M., Moerland P.D., Limou S., van Remmerden Y., Coulonges C., van Manen D., Herbeck J.T., Fellay J., Sieberer M., Sietzema J.G. et al., 2011. Plos One, 6 (2) pp. e17190.
Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure.
Lingappa J.R., Petrovski S., Kahle E., Fellay J., Shianna K., McElrath M.J., Thomas K.K., Baeten J.M., Celum C., Wald A. et al., 2011. Plos One, 6 (12) pp. e28632.
Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.
Fellay J., Frahm N., Shianna K.V., Cirulli E.T., Casimiro D.R., Robertson M.N., Haynes B.F., Geraghty D.E., McElrath M.J., Goldstein D.B. et al., 2011. Journal of Infectious Diseases, 203 (6) pp. 773-779.
Impact of phenotype definition on genome-wide association signals: empirical evaluation in human immunodeficiency virus type 1 infection.
Evangelou E., Fellay J., Colombo S., Martinez-Picado J., Obel N., Goldstein D.B., Telenti A., Ioannidis J.P., 2011. American Journal of Epidemiology, 173 (11) pp. 1336-1342.
Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.
Hitomi Y., Cirulli E.T., Fellay J., McHutchison J.G., Thompson A.J., Gumbs C.E., Shianna K.V., Urban T.J., Goldstein D.B., 2011. Gastroenterology, 140 (4) pp. 1314-1321.
Mapping of positive selection sites in the HIV-1 genome in the context of RNA and protein structural constraints.
Snoeck J., Fellay J., Bartha I., Douek D.C., Telenti A., 2011. Retrovirology, 8 p. 87.
Personalized hepatitis C therapy: opportunities and pitfalls.
Rauch A., Fellay J., 2011. Expert Review of Molecular Diagnostics, 11 (2) pp. 127-129.
Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases
Haas D.W., Kuritzkes D.R., Ritchie M.D., Amur S., Gage B.F., Maartens G., Masys D., Fellay J., Phillips E., Ribaudo H.J. et al., 2011. HIV Clinical Trials, 12 (5) pp. 277-285. Peer-reviewed.
A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro.
Yoon W., Ma B.J., Fellay J., Huang W., Xia S.M., Zhang R., Shianna K.V., Liao H.X., Haynes B.F., Goldstein D.B. et al., 2010. Aids, 24 (1) pp. 155-157.
Common genetic variants do not associate with IFN-induced neutropenia in a genome-wide association study of chronic hepatitis C patients in the ideal study
Thompson A.J., Clark P.J., Singh A., Ge D., Fellay J., Sulkowski M.S., Muir A.J., Tillman H.L., Patel K., Naggie S. et al., 2010. pp. 764A-765A dans 61st Annual Meeting of the American Association for the Study of Liver Diseases, Hepatology.
Counteraction of HLA-C-mediated immune control of HIV-1 by Nef.
Specht Anke, Telenti Amalio, Martinez Raquel, Fellay Jacques, Bailes Elizabeth, Evans David T., Carrington Mary, Hahn Beatrice H., Goldstein David B., Kirchhoff Frank, 2010. Journal of Virology, 84 (14) pp. 7300-7311.
Evidence of dysregulation of dendritic cells in primary HIV infection.
Sabado R.L., O'Brien M., Subedi A., Qin L., Hu N., Taylor E., Dibben O., Stacey A., Fellay J., Shianna K.V. et al., 2010. Blood, 116 (19) pp. 3839-3852.
Genome wide analysis of patients from the ideal study identifies a causal role for ITPA genetic variation in ribavirin-induced hemolytic anemia
Thompson A.J., Fellay J., Ge D., Urban T., Shianna K., Sulkowski M., Muir A., Afdhal N., Jacobson I., Esteban R. et al., 2010. pp. S470 dans 5th Annual Meeting of the European Association for the Study of the Liver, Journal of Hepatology. Peer-reviewed.
Genome-wide association study identifies an association between ITPA gene variants and IFN-induced thrombocytopenia in chronic hepatitis C patients from the ideal study
Thompson A.J., Singh A., Fellay J., Ge D., Sulkowski M.S., Muir A.J., Tillmann H.L., Patel K., Naggie S., Shianna K. et al., 2010. pp. 362A-363A dans 61st Annual Meeting of the American Association for the Study of Liver Diseases, Hepatology.
Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals.
Rotger M., Dang K.K., Fellay J., Heinzen E.L., Feng S., Descombes P., Shianna K.V., Ge D., Günthard H.F., Goldstein D.B. et al., 2010. Plos Pathogens, 6 (2) pp. e1000781.
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
Thompson A.J., Muir A.J., Sulkowski M.S., Patel K., Tillmann H.L., Clark P.J., Naggie S., Fellay J., Ge D., McCarthy J.J. et al., 2010. Hepatology, 52 (6) pp. 2243-2244.
Hepatitis C trials that combine investigational agents with pegylated-interferon-alpha should be stratified by IL28B genotype
Thompson A.J., Muir A.J., Sulkowski M.S., Patel K., Tillmann H.L., Clark P.J., Naggie S., Fellay J., Ge D., McCarthy J. et al., 2010. pp. 708A-709A dans 61st Annual Meeting of the American Association for the Study of Liver Diseases, Hepatology.
Host determinants of HIV-1 control in African Americans.
Pelak K., Goldstein D.B., Walley N.M., Fellay J., Ge D., Shianna K.V., Gumbs C., Gao X., Maia J.M., Cronin K.D. et al., 2010. Journal of Infectious Diseases, 201 (8) pp. 1141-1149.
Host genetics and HIV-1: the final phase?
Fellay J., Shianna K.V., Telenti A., Goldstein D.B., 2010. Plos Pathogens, 6 (10) pp. e1001033.
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.
Urban T.J., Thompson A.J., Bradrick S.S., Fellay J., Schuppan D., Cronin K.D., Hong L., McKenzie A., Patel K., Shianna K.V. et al., 2010. Hepatology, 52 (6) pp. 1888-1896.
IL28b polymorphism is associated with intrahepatic ISG expression and peginterferon-a/ribavirin response rate in chronic HCV infection.
Thompson A., Schuppan D., Urban T., Fellay J., Shianna K., McHutchison J., Goldstein D., Afdhal N., 2010. pp. S2 dans 45th Annual Meeting of the European Association for the Study of the Liver, Journal of Hepatology. Peer-reviewed.
IL28B polymorphism is associated with intrahepatic ISG expression and peginterferon-alpha/ribavirin response rate in chronic HCV infection
Thompson A.J., Urban T., Bradrick S., Fellay J., Shianna K., Schuppan D., Mchutchison J., Goldstein D., Afdhal N., 2010. pp. A122 dans Australian Gastroenterology Week 2010, Journal of Gastroenterology and Hepatology.
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., Urban T., Afdhal N.H., Jacobson I.M., Esteban R. et al., 2010. Gastroenterology, 139 (1) pp. 120-9.e18.
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
Fellay J., Thompson A.J., Ge D., Gumbs C.E., Urban T.J., Shianna K.V., Little L.D., Qiu P., Bertelsen A.H., Watson M. et al., 2010. Nature, 464 (7287) pp. 405-408. Peer-reviewed.
Role of human leukocyte antigen class I alleles in progressive multifocal leukoencephalopathy.
Gheuens S., Fellay J., Goldstein D.B., Koralnik I.J., 2010. Journal of Neurovirology, 16 (1) pp. 41-47.
The characterization of twenty sequenced human genomes.
Pelak K., Shianna K.V., Ge D., Maia J.M., Zhu M., Smith J.P., Cirulli E.T., Fellay J., Dickson S.P., Gumbs C.E. et al., 2010. Plos Genetics, 6 (9) pp. e1001111.
The genetics of HIV resistance in exposed uninfected Haemophilia A patients: an update on the CHAVI 014 protocol
Dorrell L., Shianna K.V., Fellay J., McMichael A., Goldstein D.B., 2010. p. 404 dans EAHAD 2010, 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders, Haemophilia.
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Thompson A.J., Fellay J., Patel K., Tillmann H.L., Naggie S., Ge D., Urban T.J., Shianna K.V., Muir A.J., Fried M.W. et al., 2010. Gastroenterology, 139 (4) pp. 1181-1189.
Common genetic variation and the control of HIV-1 in humans.
Fellay J., Ge D., Shianna K.V., Colombo S., Ledergerber B., Cirulli E.T., Urban T.J., Zhang K., Gumbs C.E., Smith J.P. et al., 2009/12. PLoS genetics, 5 (12) pp. e1000791. Peer-reviewed.
A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial
Fellay J., Shianna K.V., Cirulli E. T., McElrath J., Casimiro D.R., Geraghty D.E., Frahm N., Goldstein D.B., 2009. pp. P398 dans AIDS Vaccine 2009, Retrovirology.
CCL3L1 and HIV/AIDS susceptibility.
Urban T.J., Weintrob A.C., Fellay J., Colombo S., Shianna K.V., Gumbs C., Rotger M., Pelak K., Dang K.K., Detels R. et al., 2009. Nature Medicine, 15 (10) pp. 1110-1112. Peer-reviewed.
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J. et al., 2009. Nature, 461 (7262) pp. 399-401. Peer-reviewed.
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C.
Thomas Rasmi, Apps Richard, Qi Ying, Gao Xiaojiang, Male Victoria, O'hUigin Colm, O'Connor Geraldine, Ge Dongliang, Fellay Jacques, Martin Jeffrey N. et al., 2009. Nature Genetics, 41 (12) pp. 1290-1294. Peer-reviewed.
Host genetics influences on HIV type-1 disease.
Fellay J., 2009. Antiviral Therapy, 14 (6) pp. 731-738.
The Duffy Antigen Receptor for Chemokines Null Promoter Variant Does Not Influence HIV-1 Acquisition or Disease Progression
Walley N.M., Julg B., Dickson S.P., Fellay J., Ge D., Walker B.D., Carrington M., Cohen M.S., de Bakker P.I.W., Goldstein D.B. et al., 2009. Cell Host and Microbe, 5 (5) pp. 408-410.
X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women.
Siddiqui R.A., Sauermann U., Altmüller J., Fritzer E., Nothnagel M., Dalibor N., Fellay J., Kaup F.J., Stahl-Hennig C., Nürnberg P. et al., 2009. American Journal of Human Genetics, 85 (2) pp. 228-239.
The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir.
Colombo S., Rauch A., Rotger M., Fellay J., Martinez R., Fux C., Thurnheer C., Günthard H.F., Goldstein D.B., Furrer H. et al., 2008. Journal of Infectious Diseases, 198 (6) pp. 864-867. Peer-reviewed.
WGAViewer: software for genomic annotation of whole genome association studies.
Ge D., Zhang K., Need A.C., Martin O., Fellay J., Urban T.J., Telenti A., Goldstein D.B., 2008. Genome Research, 18 (4) pp. 640-643.
A whole-genome association study of major determinants for host control of HIV-1
Fellay J., Shianna K. V., Ge D., Colombo S., Ledergerber B., Weale M., Zhang K., Gumbs C., Castagna A., Cossarizza A. et al., 2007/08. Science, 317 (5840) pp. 944-947. Peer-reviewed.
Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification.
Keiser O., Fellay J., Opravil M., Hirsch H.H., Hirschel B., Bernasconi E., Vernazza P.L., Rickenbach M., Telenti A., Furrer H., 2007. Antiviral Therapy, 12 (8) pp. 1157-1164. Peer-reviewed.
Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation.
Manuel O., Venetz J.P., Fellay J., Wasserfallen J.B., Sturzenegger N., Fontana M., Matter M., Meylan P.R., Pascual M., 2007. Swiss Medical Weekly, 137 (47-48) pp. 669-676. Peer-reviewed.
Host genetics: fine-tuning innate signaling.
Fellay J., Goldstein D.B., 2007. Current Biology, 17 (13) pp. R516-R518.
HIV and solid organ transplantation: the Swiss experience.
Müller N.J., Furrer H., Kaiser L., Hirschel B., Cavassini M., Fellay J., Chave J.P., Wüthrich R.P., Weber M., Müllhaupt B. et al., 2006/03/18. Swiss medical weekly, 136 (11-12) pp. 194-196. Peer-reviewed.
Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir.
Fellay J., Venetz J.P., Aubert J.D., Seydoux C., Pascual M., Meylan P.R., 2005. Transplantation Proceedings, 37 (2) pp. 949-951. Peer-reviewed.
Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir.
Fellay J., Venetz J.P., Pascual M., Aubert J.D., Seudoux C., Meylan P.R., 2005. American Journal of Transplantation, 5 (7) pp. 1781-2; author reply 1783.
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
Fellay J., Marzolini C., Decosterd L., Golay K.P., Baumann P., Buclin T., Telenti A., Eap C.B., 2005. European journal of clinical pharmacology, 60 (12) pp. 865-73. Peer-reviewed.
CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene.
Eap C.B., Fellay J., Buclin T., Bleiber G., Golay K.P., Brocard M., Baumann P., Telenti A., 2004. Pharmacogenetics, 14 (4) pp. 255-260. Peer-reviewed.
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Fellay J., Telenti A., Biollaz J., Buclin T., 2003. Clinical pharmacology and therapeutics, 73 (1) pp. 20-30. Peer-reviewed.
HIV lipoatrophy and mosquito bites
Greub G., Fellay J., Telenti A., 2002/01. Clinical Infectious Diseases, 34 (2) pp. 288-289.
Multidrug resistance and response to antiretroviral treatment - Reply
Fellay J., Back D., Schinkel A.H., Eap C.B., Telenti A., 2002. The Lancet, 359 (9323) pp. 2114-2115.
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G. et al., 2002. The Lancet, 359 (9300) pp. 30-36. Peer-reviewed.
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Fellay J., Boubaker K., Ledergerber B., Bernasconi E., Furrer H., Battegay M., Hirschel B., Vernazza P., Francioli P., Greub G. et al., 2001. Lancet, 358 (9290) pp. 1322-1327.
Unicentre - CH-1015 Lausanne
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University